Sumitomo Pharma (DNPUF) Stock Price, News & Analysis

Company Overview

Sumitomo Pharma Co., Ltd., trading OTC under the ticker DNPUF, is a global pharmaceutical company headquartered in Osaka, Japan. It engages in the research, development, manufacturing and marketing of prescription medicines. As part of the broader Sumitomo Group, the company applies integrated drug discovery platforms and collaborative partnerships to bring innovative therapies to market.

The company’s portfolio encompasses central nervous system disorders, oncology, immunology and regenerative medicine. Sumitomo Pharma develops small molecules and biologics for conditions such as depression, schizophrenia, epilepsy and various solid tumors. In addition to its in-house pipeline, the company pursues strategic licensing agreements and joint research initiatives to enhance its product offerings, while exploring emerging modalities including gene therapy and digital health solutions.

Sumitomo Pharma maintains research and production facilities in Japan and operates subsidiaries across North America, Europe and the Asia-Pacific region, notably Sunovion Pharmaceuticals, Inc. in the United States. Its global sales and distribution network spans over 30 countries, supported by regional R&D hubs in major life-science centers to accelerate clinical development and regulatory approvals.

Formed in October 2005 through the merger of Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceuticals Co., Ltd., the company’s lineage dates to the late 19th century. Led by an Osaka-based executive team, Sumitomo Pharma continues to prioritize scientific innovation, patient-centered therapies and sustainable growth in the international biopharmaceutical landscape.

Key Stats

• Today's Range: $10.50 to $10.50
• 50-Day Range: $10.50 to $14.82
• 52-Week Range: $6.34 to $19.20
• Volume: 118 shs
• Average Volume: 1,530 shs
• Market Capitalization: N/A
• P/E Ratio: 0.18
• Dividend Yield: 136.87%
• Price Target: N/A
• Consensus Rating: N/A

Sumitomo Pharma Stock Analysis - MarketRank™

Sumitomo Pharma scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sumitomo Pharma.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sumitomo Pharma is 0.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sumitomo Pharma is 0.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.65.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sumitomo Pharma has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Sumitomo Pharma has recently decreased by 15.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Sumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sumitomo Pharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sumitomo Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

7.58% of the stock of Sumitomo Pharma is held by institutions.

Company Calendar

• Today: 5/12/2026
• Next Earnings (Estimated): 5/19/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DNPUF
• CIK: N/A
• Web: www.ds-pharma.com
• Phone: 81 6 6203 5321
• Fax: N/A
• Employees: 6,250
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.18
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A